A SPAC deal with RA Capital–sponsored RACC is expected to yield ~$175 million gross, including a fully backstopped trust and PIPE/SAFE financing, with closing targeted by end of 2026. Rugonersen, an ...

Project Trialblazer prioritizes reducing IND review timelines, but its impact on sponsor behavior may be limited when ...

Within your prior big pharma employers, AI is now a core competitive capability as it has shortened target identification and optimized molecule design. As building world-class AI drug-discovery ...

FDA authorization covers adults and children ≥6 years (≥20 kg) for once-daily centanafadine ER, positioned as a CNS stimulant with a first-in-class NDSRI mechanism. Evidence derived from four pivotal ...

This past May, Pharmaceutical Executive reported that CVS Health decided to return Eli Lilly’s Zepbound to its list of ...

Specialty pharma launches depend heavily on data from outside the organization. Distributors, third-party logistics providers ...

Since then, that mindset has continued to grow at AbbVie.

Indication includes adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, for LDL-C ...

TRIUMPH-2 (n=1,152) met its primary endpoint, showing 12.7%–20.8% mean weight loss across 4–12 mg versus 4.0% with placebo at 80 weeks. Glycemic efficacy in TRIUMPH-2 included A1C reductions up to 1.6 ...

EUA marks the first U.S. multiplex PCR capable of differential detection of HSV-1, HSV-2, VZV, and MPXV from a single specimen. Overlapping lesion morphology makes sequential single-pathogen testing ...

Narrow votes supported compounding of BPC-157, KPV, and TB-500 (8-6; one abstention) and MOTS-c (7-5; two abstentions), without constituting FDA approval or demonstrated clinical benefit. Regulatory ...

A stepped tariff schedule targets generics only, preserving existing treatment for patented and innovative drugs while signaling punitive intent for firms that do not invest in U.S. plant and ...